Feature | May 17, 2013

First Implant Made for Barostim neo Device to Treat Hypertension

It is designed to use the body's own natural blood flow regulation system to treat hypertension.

May 17, 2013 — Prof. Dr. Béla Merkely and Dr. Péter Sótonyi at Semmelweis Egyetem Kardiológiai Központ in Hungary completed the first patient implant of the Barostim neo device for hypertension. Barostim neo is a small, easy to implant device manufactured by CVRx.

Barostim neo is designed to use the body's own natural blood flow regulation system to treat hypertension. The system works by electrically activating baroreceptors, the body's natural blood pressure sensors that regulate cardiovascular function. When the Barostim neo is activated, signals are sent through neural pathways to the brain, which responds by telling the arteries to relax, the heart to slow down and the kidneys to reduce fluid in the body, lowering excessive blood pressure and workload on the heart.

“Barostim Therapy will provide clinical benefits to our patients in a cost-effective manner. Studies on the device have shown significant, sustained blood pressure reduction which can help reduce the health risks associated with hypertension, such as stroke and kidney failure, and help improve an individual's quality of life,” said Merkely, director at Semmelweis Egyetem Kardiológiai Központ

Barostim neo is a second-generation device that uses CVRx-patented technology that is designed to trigger the body's own natural blood flow regulation system to treat hypertension and heart failure. The system works by electrically activating the baroreceptors, the body's natural blood pressure sensors that regulate cardiovascular function. These baroreceptors are located on the carotid artery. When activated by Barostim neo, signals are sent through neural pathways to the brain, which responds by telling the:

  • Arteries to relax, making it easier for blood to flow through the body and reducing cardiac exertion;
  • Heart to slow down, allowing more time for the organ to fill with blood; and
  • Kidneys to reduce fluid in the body, lowering both excessive blood pressure and workload on the heart.

This patented technology has the potential to improve quality of life and reduce health risks associated with hypertension and heart failure, including heart and kidney disease, stroke and death. Other potential benefits of Barostim neo include that it:

  • Can be adjusted to meet each patient's individual therapy needs, making it the only personalized medical device therapy for the treatment of hypertension with a CE marking;
  • Is a non-destructive reversible treatment; and
  • Provides 100% compliance to treatment, by automatically and continuously activating the baroreflex.

 

For more information: www.cvrx.com

Related Content

Abbott recalls its NC Balloon catheters
News | Balloon Catheter| May 22, 2017
May 22, 2017 — Abbott Vascular has initiated a voluntary recall of specific lots of three catheters due to 19 reports
Contego Medical Receives CE Mark for Vanguard IEP Peripheral Balloon Angioplasty System
News | Peripheral Arterial Disease (PAD)| May 17, 2017
Contego Medical LLC announced recently that it has received CE Marking of its Vanguard IEP Peripheral Balloon...
Early Treatment for NSTEMI Patients Shows Greater Rate of Survival
News | Cath Lab| May 16, 2017
An analysis of non ST-elevation myocardial infarction (NSTEMI) patients who undergo coronary revascularization within...
Large Multicenter Study Shows High Success Rate for Robotic PCI Procedures, SCAI, Corindus CorPath 200
News | Robotic Systems| May 16, 2017
The largest real-world study of robotic percutaneous coronary intervention (PCI) demonstrated clinical and technical...
Adept Medical Launches IR Platform, interventional radiology
Technology | Cath Lab| May 16, 2017
Adept Medical announced the launch of the IR Platform, designed as an over-patient work surface for vascular and...
Race, Gender and Socioeconomic Factors Impact PCI Outcomes, PLATINUM Diversity study, SCAI 2017
News | Cath Lab| May 15, 2017
A first-of-its-kind study discovered that women and minorities who underwent a percutaneous coronary intervention (PCI...
Analysis Looks at Role Type of Valve Plays in Patient Outcomes Post-TAVR
News | Heart Valve Technology| May 15, 2017
For patients who undergo transcatheter aortic valve replacement (TAVR), their risk factors, not the type of valve used...
Day of the Week PCI-Related Hospitalization Occurs Determines Likelihood of Survival, SCAI 2017
News | Cath Lab| May 15, 2017
In a large-scale analysis of percutaneous coronary intervention (PCI)-related hospitalizations, people admitted to the...
First Pennsylvania Patient Treated in LEADERS FREE II Trial of BioFreedom Drug-Coated Stent
News | Stents Drug Eluting| May 12, 2017
PinnacleHealth CardioVascular Institute enrolled the first patient in Pennsylvania in a trial assessing the safety and...
Overlay Init